Loading clinical trials...
Loading clinical trials...
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia
Conditions
Interventions
HT-6184
Locations
10
India
Hemato Oncology Clinica Ahmedabad Pvt. Ltd. Vedanta Institute of Medical Sciences
Ahmedabad, Gujarat, India
Shalby Hospital
Ahmedabad, Gujarat, India
Malabar Cancer Center
Kannur, Kerala, India
HCG Cancer Center Vizag
Visakhapatnam, Krishna, India
Dr. Bafna's Star Superspeciality Clinic and Hospital
Kolhāpur, Maharashtra, India
All India Institute of Medical Sciences
Dehradun, Rishkesh, India
Start Date
December 9, 2023
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2026
Last Updated
December 19, 2025
NCT03520647
NCT06859424
NCT06484062
NCT06994676
NCT07270978
NCT05292664
Lead Sponsor
Halia Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions